The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).
 
Jean H. Hoffman-Censits
No Relationships to Disclose
 
Petros Grivas
No Relationships to Disclose
 
Michiel Simon Van Der Heijden
No Relationships to Disclose
 
Robert Dreicer
No Relationships to Disclose
 
Yohann Loriot
No Relationships to Disclose
 
Margitta Retz
No Relationships to Disclose
 
Nicholas J. Vogelzang
No Relationships to Disclose
 
Jose Luis Perez-Gracia
No Relationships to Disclose
 
Arash Rezazadeh
No Relationships to Disclose
 
Sergio Bracarda
No Relationships to Disclose
 
Evan Y. Yu
No Relationships to Disclose
 
Christopher J. Hoimes
No Relationships to Disclose
 
Joaquim Bellmunt
No Relationships to Disclose
 
David I. Quinn
No Relationships to Disclose
 
Daniel Peter Petrylak
No Relationships to Disclose
 
Syed A. Hussain
No Relationships to Disclose
 
Na Cui
No Relationships to Disclose
 
Sanjeev Mariathasan
No Relationships to Disclose
 
Oyewale O. Abidoye
No Relationships to Disclose
 
Jonathan E. Rosenberg
No Relationships to Disclose